Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer
- PMID: 15181134
Predictive value for disease progression of serum thyroglobulin levels measured in the postoperative period and after (131)I ablation therapy in patients with differentiated thyroid cancer
Abstract
The aim of our study was to evaluate and compare in thyroid cancer patients the predictive value for disease progression of thyroglobulin (Tg) levels measured under thyroid-stimulating hormone (TSH) stimulation, in the postoperative period just before (131)I ablative therapy and at the time of control 6-12 mo later.
Methods: Two-hundred twelve consecutive patients treated for a well-differentiated thyroid carcinoma (184 papillary, 28 follicular) with no initial distant metastases were retrospectively studied. All patients had a total or near-total thyroidectomy followed by ablation with 3.7 GBq (131)I. Tg levels were determined just before ablative therapy (Tg1) and 6-12 mo later (Tg2). Thresholds of 30 and 10 ng/mL were used for Tg1 and Tg2, respectively. Univariate and multivariate analyses were performed to assess the predictive value for disease progression of the 2 Tg determinations.
Results: Thirty patients had a Tg1 level > 30 ng/mL. Six to 12 mo later, 30 patients had a Tg2 level > 10 ng/mL, 19 of whom had initially a Tg1 level > 30 ng/mL. Disease progression was reported in 20 patients (9%). Progression-free survival rates were significantly lower in patients with a low Tg1 or Tg2 level but the difference was more important with Tg2. With univariate analysis, 5 variables were significantly associated with disease progression: Tg2, Tg1, node invasion, extrathyroidal extension, and tumor size. With multivariate analysis, only Tg2 (odds ratio [OR] = 16.4; 95% confidence interval [95% CI] = 5.7-47.4; P < 0.001) and node invasion (OR = 2.7; 95% CI = 1.0-7.2; P = 0.04) had an independent prognostic value. When only initial parameters were considered, Tg1 and node invasion were the 2 independent prognostic factors. The OR decreased for Tg1 (OR = 10.1; 95% CI = 4.0-25.7; P < 0.001) but increased for node invasion (OR = 4.4; 95% CI = 1.7-11.2; P = 0.002).
Conclusion: Among all clinical and tumoral variables, lymph node invasion and serum Tg level are 2 important parameters to define the risk of disease progression. Although Tg2 appears more significant than Tg1, both Tg levels measured under TSH stimulation, in the postoperative period and a few months after ablative therapy, have a predictive value. In clinical practice, patients at risk can be selected as soon as the initial lymph node status and Tg1 level are known.
Similar articles
-
Prognostic implication of thyroglobulin and quantified whole body scan after initial radioiodine therapy on early prediction of ablation and clinical response for the patients with differentiated thyroid cancer.Ann Nucl Med. 2012 Dec;26(10):777-86. doi: 10.1007/s12149-012-0640-1. Epub 2012 Aug 7. Ann Nucl Med. 2012. PMID: 22869417
-
Long-term follow-up of patients with papillary and follicular thyroid cancer: a prospective study on 715 patients.J Clin Endocrinol Metab. 2011 May;96(5):1352-9. doi: 10.1210/jc.2010-2708. Epub 2011 Mar 9. J Clin Endocrinol Metab. 2011. PMID: 21389143
-
Persistent disease and recurrence in differentiated thyroid cancer patients with undetectable postoperative stimulated thyroglobulin level.Endocr Relat Cancer. 2011 Mar 3;18(2):R29-40. doi: 10.1677/ERC-10-0292. Print 2011 Apr. Endocr Relat Cancer. 2011. PMID: 21183629 Review.
-
Comparison of seven serum thyroglobulin assays in the follow-up of papillary and follicular thyroid cancer patients.J Clin Endocrinol Metab. 2007 Jul;92(7):2487-95. doi: 10.1210/jc.2006-0723. Epub 2007 Apr 10. J Clin Endocrinol Metab. 2007. PMID: 17426102 Clinical Trial.
-
Clinical and laboratory follow-up in differentiated thyroid carcinoma.Rays. 2000 Apr-Jun;25(2):239-44. Rays. 2000. PMID: 11370541 Review. English, Italian.
Cited by
-
Value of follow-up diagnostic radioiodine scans in differentiated thyroid cancer.Endocr Connect. 2024 Apr 12;13(5):e240007. doi: 10.1530/EC-24-0007. Print 2024 May 1. Endocr Connect. 2024. PMID: 38513355 Free PMC article.
-
Stimulating thyroglobulin to TSH ratio predict long-term efficacy of 131I therapy in patients with differentiated thyroid cancer after total thyroidectomy: a retrospective study.Endocrine. 2024 Jun;84(3):1064-1071. doi: 10.1007/s12020-023-03663-6. Epub 2024 Jan 3. Endocrine. 2024. PMID: 38172344
-
Usefulness of second 131I treatment in biochemical persistent differentiated thyroid cancer patients.Eur Thyroid J. 2023 Oct 18;12(6):e230052. doi: 10.1530/ETJ-23-0052. Print 2023 Dec 1. Eur Thyroid J. 2023. PMID: 37855417 Free PMC article.
-
Differential distribution and prognostic value of CD4+ T cell subsets before and after radioactive iodine therapy in differentiated thyroid cancer with varied curative outcomes.Front Immunol. 2022 Aug 26;13:966550. doi: 10.3389/fimmu.2022.966550. eCollection 2022. Front Immunol. 2022. PMID: 36091039 Free PMC article.
-
Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review.Iran J Pharm Res. 2022 May 14;21(1):e123825. doi: 10.5812/ijpr-123825. eCollection 2022 Dec. Iran J Pharm Res. 2022. PMID: 36060901 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous